CompletedNot Applicable

Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients

Egypt120 participantsStarted 2023-05-01

Plain-language summary

This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 21 years. * Both genders. * Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion. Exclusion Criteria: * Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place. * History of allergy to taurolidine, tigecycline, heparin, and citrate.

What they're measuring

Positive bacterial growth

Timeframe: 30 days after the procedure

Trial details

NCT IDNCT07366372

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-01

View on ClinicalTrials.gov More Taurolidine trials